Absence of osteoclastogenic response to pooled polyclonal anti-citrullinated peptide/protein antibodies from patients with rheumatoid arthritis in vitro
Xiaoli Chen, Zhuo An, Changhong Li, Jinxia Zhao · 2026
Read Absence of osteoclastogenic response to pooled polyclonal anti-citrullinated peptide/protein antibodies from patients with rheumatoid arthritis in vitro by Xiaoli Chen, Zhuo An, Changhong Li, Jinxia Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13526721.txt.
Description
Xiaoli Chen, Zhuo An, Changhong Li, and Jinxia Zhao test, in a 2026 lab study, whether pooled antibodies from rheumatoid arthritis patients can drive the bone eating cells behind joint erosion. These anti-citrullinated protein antibodies mark the disease, yet their direct effect on osteoclast growth was debated. Antibodies were purified from pooled blood of 37 positive patients.
Purified antibodies kept an intact structure and bound citrullinated vimentin. Monocytes from healthy donors and patients were then grown into osteoclasts with standard growth factors, with or without the antibodies. Antibody treatment did not clearly raise osteoclast numbers, marker gene expression, or bone resorption pit area against controls. The authors conclude any bone effect likely needs a richer tissue setting or special antibody properties their setup missed.
Catalog record
| CREATOR | Xiaoli Chen, Zhuo An, Changhong Li, Jinxia Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37622 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |